Sort
51,593 grants matching “hepatitis”
Mechanisms of Insulin Resistance in Man
$553,065Rita Basu · Mayo Clinic Rochester · R01 · FY2013 · DK
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
$553,056Ethan Perlstein · Maggie'S Pearl, Llc · R44 · FY2023 · DK
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
$553,056Ethan Perlstein · Maggie'S Pearl, Llc · R44 · FY2024 · DK
Hepatitis C virus genome structure: dynamic roles in replication and infectivity
$553,036Anna Marie Pyle · Yale University · R01 · FY2020 · AI
Medication Adherence in Children Who Had a Liver Transplant (MALT)
$553,020Eyal Shemesh · Icahn School Of Medicine At Mount Sinai · R01 · FY2014 · DK
Targeted chemotherapy delivery and capture
$552,870Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2017 · EB
Mechanisms Linking Nonmedical Prescription Drug Use and Injection Drug Use
$552,860Scott Novak · Research Triangle Institute · R01 · FY2011 · DA
Developing Methods for Precise, Safe and Target-location Specific Histotripsy of Liver Tumors
$552,836Timothy J Ziemlewicz · University Of Wisconsin-Madison · R01 · FY2021 · CA
Transcriptional regulatory mechanisms in B cell development and leukemogenesis
$552,794Robert G Roeder · Rockefeller University · R01 · FY2013 · CA
Mechanisms of Silymarin Hepatoprotection
$552,791Stephen J. Polyak · University Of Washington · R01 · FY2012 · AT
Etiology of Persistent Microalbuminuria in Nigeria
$552,775William Wester · Vanderbilt University Medical Center · R01 · FY2022 · DK
Training Program in Substance Use, HIV and Related Infections
$552,749Natasha Martin · University Of California, San Diego · T32 · FY2023 · DA
Medication development of agonist-type treatment agents for stimulant addiction
$552,709Richard Rothman · National Institute On Drug Abuse · ZIA · FY2011 · DA
The Innate Immune Response in the Marmoset Model of GBV-B Infections: A Surrogate
$552,679Robert E Lanford · Texas Biomedical Research Institute · R01 · FY2012 · AI
The Innate Immune Response in the Marmoset Model of GBV-B Infections: A Surrogate
$552,679Robert E Lanford · Texas Biomedical Research Institute · R01 · FY2014 · AI
Using CAI to Enhance Drug Tx Staff HCV Knowledge and Communication Skills
$552,649Hilary James Liberty · Social Sciences Innovations Corporation · R44 · FY2010 · DA
Epigenetic regulation of development and liver regeneration by UHRF1
$552,646Kirsten C Sadler Edepli · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · DK
Glycopathology of HCC: identification of the source cells of serum fucosylation
$552,594Anand S Mehta · Medical University Of South Carolina · U01 · FY2019 · CA
PNPLA3 in Susceptibility and Resistance to Fatty Liver Disease
$552,559Helen H. Hobbs · Ut Southwestern Medical Center · R01 · FY2024 · DK
Insulin Signaling, Lipoproteins and Atherosclerosis
$552,549Alan Richard Tall · Columbia University Health Sciences · P01 · FY2007 · HL
M2 peptide based vaccines against influenza
$552,548Washington University · U01 · FY2005 · AI
Animal and plant proteins and glucose metabolism
$552,499Bettina Mittendorfer · Washington University · R01 · FY2019 · DK
Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
$552,492Michael Karin · University Of California, San Diego · R01 · FY2021 · CA
Chronic Hepatitis Intervention Project for Drug Users
$552,462Research Triangle Institute · R01 · FY2004 · DA
Risk Reduction for Young African American IDUs
$552,450Tulane University Of Louisiana · R01 · FY2003 · DA